CircRNAs in Lung Adenocarcinoma: Diagnosis and Therapy

Curr Gene Ther. 2022;22(1):15-22. doi: 10.2174/1566523221666211202095258.

Abstract

Lung adenocarcinoma (LUAD) is the common histological subtype of non-small-cell lung carcinoma (NSCLC). Circular RNAs (circRNAs) represent a new class of non-coding RNAs (ncRNAs) involved in the development of cancer. Accumulating evidence indicated that a large number of circular RNAs were found to be involved in many biological processes, including tumor initiation, proliferation and progression. These circRNAs present great potentials as new biomarkers and vital targets for disease diagnosis and prognosis. In this review, we mainly focus on the differentially expressed circRNAs and their functions in the pathogenesis of LUAD, which makes it possible for the utility of circRNAs as novel biomarkers for early diagnosis and therapy. Especially, it is helpful to develop circRNAs as crucial therapeutic targets, thus providing a promising biomedical application in the field of cancer gene therapy.

Keywords: Circular RNA; application; biomarker; diagnosis; lung adenocarcinoma; therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenocarcinoma of Lung* / diagnosis
  • Adenocarcinoma of Lung* / genetics
  • Adenocarcinoma of Lung* / therapy
  • Biomarkers
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / therapy
  • RNA, Circular / genetics

Substances

  • Biomarkers
  • RNA, Circular